$2.15... November 4, 2025: Immuron announced that the U.S. FDA has approved its Investigational New Drug (IND) application for IMM-529, allowing it to proceed with a Phase 2 trial planned for H1 2026. The trial will enroll about 60 subjects with a focus on safety, tolerability, and efficacy measures including mortality, disease symptoms, and recurrence rates. IMM-529 targets Clostridioides difficile infection with strong preclinical data supporting its development. The market potential is estimated at $400 million if positioned at first recurrence..
Market Data 
Markets 
AI
